Bill and Melinda Gates Foundation: Grand Challenges – Emerging Technologies for New Solutions in Global Health (Round 23)
Emerging Technologies for New Solutions in Global Health will support projects that apply an emerging technology – or a combination of emerging technologies – for new and potentially transformative solutions in global health priority areas. Priority areas encompass infectious disease outcomes, pregnancy and birth outcomes, child growth and development outcomes, disease surveillance, and research for the development of new vaccines, drugs (including non-hormonal contraceptives), and diagnostics. For background on the priority areas, read the summaries of the strategies being employed by the teams within the global health division at the Gates foundation: Discovery and Translational Sciences; Enteric and Diarrheal Diseases; HIV; Malaria; Maternal, Newborn, and Child Health Discovery and Tools; Neglected Tropical Diseases; Pneumonia; Tuberculosis; Vaccine Development and Surveillance.
Examples of the types of applications of emerging technologies that would be considered include, but are not limited to:
- Artificial intelligence for image analysis of human patients (e.g., fetal ultrasound, infant optical neuroimaging, or infant video data) or human biosamples (e.g., tissue sample microscopy or placental morphology) to reveal predictive biomarkers of adverse health outcomes or correlates of resilience
- Materials science for the design of laboratory model systems enabling investigation of new aspects of disease mechanisms (including pathogen persistence) or response to therapy, or enabling high-throughput screening assays (including culture systems to recapitulate complex biological systems)
- Wearable sensors to provide early indicators of treatment response, to identify causal factors underlying adverse pregnancy and birth outcomes, or to continuously monitor systemic metabolites to understand baselines and temporal fluctuation for biomarkers of health and disease
- Synthetic biology approaches to develop highly sensitive diagnostics
- Nanotechnology for the creation of sensitive and specific biosensors
- Microscopy for intravital imaging of organ systems to reveal actionable mechanisms to prevent infectious disease pathogenesis or foster robust immune response
- Augmented reality to improve the quality of patient care through interactive guidance for diagnostic procedures
- Virtual reality to simulate host-pathogen interactions for insights into the design of agents to protect against infectious disease
- Geospatial mapping to understand and predict temporal changes in disease burden and design geographically-targeted interventions
- Robotics to enable new drug screening systems
- DNA sequencing combined with data analytical methods to facilitate a transkingdom view of the microbiota across body sites, including potential microbiota-mediated interactions between body sites
Amount: Awards of $100,000 USD are made in Phase I. Phase I awardees have one opportunity to apply for a follow-on Phase II award of up to $1,000,000.
Eligibility: Foreign and domestic organizations, including non-profit organizations, for-profit companies, international organizations, government agencies, and academic institutions.
This post was filed under: